Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ypf Tecnología S A currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter constitutes the entirety of the company's current prosecution activity at the patent office. The focus on this technology area suggests a strategic interest in biological or pharmaceutical innovations that require rigorous examination.
The portfolio's examination is handled by 1 distinct examiner within 1 distinct art unit. This high degree of centralization means that the company's prosecution strategy does not need to account for varying interpretations across different examiners or units. The 1 distinct art unit provides a singular regulatory environment for the company's pending claims and legal arguments.
KANE, TREVOR LOGAN is the busiest examiner for the portfolio, with 1 busiest examiner pending action currently under review. Monitoring the specific preferences and past decisions of this individual is a critical component of the current prosecution strategy. The timeline for resolution is directly tied to the workload and review pace of this specific examiner.
With only 1 distinct examiner to manage, the company can dedicate its full attention to the specific requirements of the Biotechnology & Pharmaceuticals field. The 1 pending office action represents the critical path for the company's current intellectual property goals and future patent holdings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KANE, TREVOR LOGAN | 1 | 69.4% | +52.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18495900 | TRICHODERMA-BASED BIOENHANCER FOR FOLIAR APPLICATION IN PLANTS | KANE, TREVOR LOGAN | 17d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18495900 | TRICHODERMA-BASED BIOENHANCER FOR FOLIAR APPLICATION IN PLANTS | KANE, TREVOR LOGAN | 17d overdue |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18495900 | TRICHODERMA-BASED BIOENHANCER FOR FOLIAR APPLICATION IN PLANTS | KANE, TREVOR LOGAN | 1657 | §101§103§112Other | Non-Final OA | 17d overdue | Pending | Oct 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial